(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 September 2025 (04.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/181830 A3

(51) International Patent Classification:
C07D 471/04 (2006.01) *C07D 487/04* (2006.01)
C07D 519/00 (2006.01) *A61P 35/00* (2006.01)
C07D 401/14 (2006.01)

(21) International Application Number:
PCT/IN2025/050290

(22) International Filing Date:
28 February 2025 (28.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202411015473 01 March 2024 (01.03.2024) IN

(71) Applicant: **JUBILANT EPIPAD LLC** [US/US]; 790 Township Line Road, Suite 325, Yardley, PA, Pennsylvania 19067 (US).

(72) Inventor; and
(71) Applicant: **RAJAGOPAL, Sridharan** [IN/IN]; Jubilant Therapeutics India Ltd, # 96, Industrial Suburb, 2nd Stage, Industrial Area, Yeshwanthpur, Karnataka, Bangalore 560022 (IN).

(72) Inventors: **SADHU, Naveen**; Jubilant Therapeutics India Ltd, # 96, Industrial Suburb, 2nd Stage, Industrial Area, Yeshwanthpur, Karnataka, Bangalore 560022 (IN).
GAJENDRAN, Chandru; Jubilant Therapeutics India Ltd, # 96, Industrial Suburb, 2nd Stage, Industrial Area, Yeshwanthpur, Karnataka, Bangalore 560022 (IN).

(74) Agent: **LAKSHMIKUMARAN, Malathi** et al.; B6/10, Safdarjung Enclave, New Delhi 110029 (IN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) Date of publication of the international search report:
09 October 2025 (09.10.2025)

WO 2025/181830 A3

(54) Title: POLYHETEROCYCLIC COMPOUNDS AS PEPTIDYL ARGININE DEIMINASE 4 (PAD4) INHIBITORS

(57) Abstract: The present disclosure provides polyheterocyclic compounds of Formula (I) that are PAD4 inhibitors. The present disclosure also provides a process for preparing the compounds of Formula (I). The compounds of the present disclosure are efficient PAD inhibitors and are useful in treating diseases that are mediated by PAD. The compounds of the present disclosure are PAD4 inhibitors and are all capable of inhibiting PAD4 enzyme. The compounds of the present disclosure either alone or in combination with other clinically relevant agent inhibits PAD4 enzyme.